# reload+after+2024-01-20 18:45:05.382782
address1§3013 Science Park Road
address2§Suite 200
city§San Diego
state§CA
zip§92121
country§United States
phone§858 684 1300
website§https://www.gossamerbio.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colonystimulating factor 1 receptor, or CSF1R, and c-KIT inhibitor for the treatment of pulmonary arterial hypertension; GB004, a gut-targeted, oral small molecule for the treatment of inflammatory bowel disease; GB5121, an oral, irreversible, covalent, small molecule inhibitor of Bruton's Tyrosine Kinase for the treatment of primary central nervous system lymphoma; and GB7208, an oral, small molecule, BTK inhibitor for the treatment of multiple sclerosis. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds; and Aerpio Pharmaceuticals, Inc. to develop and commercialize GB004 and related compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.
fullTimeEmployees§178
companyOfficers§[{'maxAge': 1, 'name': 'Mr. Faheem  Hasnain', 'age': 65, 'title': 'Co-Founder, CEO, President & Chairman', 'yearBorn': 1958, 'fiscalYear': 2022, 'totalPay': 902525, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Bryan  Giraudo', 'age': 48, 'title': 'COO & CFO', 'yearBorn': 1975, 'fiscalYear': 2022, 'totalPay': 690593, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Richard  Aranda M.D.', 'age': 63, 'title': 'Chief Medical Officer', 'yearBorn': 1960, 'fiscalYear': 2022, 'totalPay': 625241, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Christian  Waage', 'age': 56, 'title': 'Executive Vice President of Technical Operations & Administration', 'yearBorn': 1967, 'fiscalYear': 2022, 'totalPay': 583156, 'exercisedValue': 0, 'unexercisedValue': 20005}, {'maxAge': 1, 'name': 'Mr. Jeff  Boerneke', 'title': 'General Counsel & Secretary', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Deanna  Weber', 'title': 'Senior Vice President of Human Resources', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Mario  Orlando', 'title': 'Senior Vice President of Commercial New Product Planning', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Caryn L. Peterson', 'age': 64, 'title': 'Executive Vice President of Regulatory Affairs', 'yearBorn': 1959, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Matt  Cravets', 'title': 'Senior Vice President of Biometrics', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Lisa Elizabeth Nolan Ph.D.', 'age': 61, 'title': 'MD & President of Gossamer Bio Ireland', 'yearBorn': 1962, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§7
boardRisk§8
compensationRisk§10
shareHolderRightsRisk§8
overallRisk§9
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§4
payoutRatio§0.0
beta§1.569
currency§USD
dateShortInterest§1702598400
forwardEps§-0.8
pegRatio§-0.15
exchange§NMS
quoteType§EQUITY
shortName§Gossamer Bio, Inc.
longName§Gossamer Bio, Inc.
firstTradeDateEpochUtc§1549636200
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§b23a77d9-f4eb-3e8f-858d-367c07bb4901
gmtOffSetMilliseconds§-18000000
targetHighPrice§15.0
targetLowPrice§0.5
targetMeanPrice§5.47
targetMedianPrice§4.5
recommendationMean§2.4
recommendationKey§buy
numberOfAnalystOpinions§8
quickRatio§7.772
grossMargins§0.0
ebitdaMargins§0.0
trailingPegRatio§None
